Randi G. Syljuåsen is Head of the Radiation Biology and DNA
damage signaling group at the Department of Radiation Biology, Institute for
Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Norway.
She received an M.Sc. from The Norwegian Institute of Technology (NTNU) in 1991
and a Ph.D. from the University of California, Los Angeles (UCLA) in 1996. She
carried out Postdoc research at the Department of Radiation Oncology, UCLA from 1996 to
1997, at the Laboratory of Radiobiology, Harvard School of Public Health from
1997 to 1998, and at the Department of Cell Cycle and Cancer, The Danish Cancer
Society from 1999 to 2006. She served as a Guest researcher at the BRIC
Biocenter, Copenhagen University for 6 months in 2007. Then, she joined as
project group leader in the Department of Radiation Biology, Institute for
Cancer Research, Norwegian Radium Hospital, Oslo University Hospital in 2007,
and became Group Leader in 2012. Her group goal is to uncover novel mechanisms
within the network of intracellular DNA damage signaling pathways and
understand how inhibitors targeting DNA damage signaling and repair can be
utilized to improve cancer treatment.
Randi G. Syljuåsen is Head of the Radiation Biology and DNA
damage signaling group at the Department of Radiation Biology, Institute for
Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Norway.
She received an M.Sc. from The Norwegian Institute of Technology (NTNU) in 1991
and a Ph.D. from the University of California, Los Angeles (UCLA) in 1996. She
carried out Postdoc research at the Department of Radiation Oncology, UCLA from 1996 to
1997, at the Laboratory of Radiobiology, Harvard School of Public Health from
1997 to 1998, and at the Department of Cell Cycle and Cancer, The Danish Cancer
Society from 1999 to 2006. She served as a Guest researcher at the BRIC
Biocenter, Copenhagen University for 6 months in 2007. Then, she joined as
project group leader in the Department of Radiation Biology, Institute for
Cancer Research, Norwegian Radium Hospital, Oslo University Hospital in 2007,
and became Group Leader in 2012. Her group goal is to uncover novel mechanisms
within the network of intracellular DNA damage signaling pathways and
understand how inhibitors targeting DNA damage signaling and repair can be
utilized to improve cancer treatment.